Microcap Ledger Bionano Genomics, Inc. $BNGO
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Laboratory Analytical Instruments
- Headquarters
- San Diego, CA
- Fiscal year end
- December 31
- Shares outstanding
- 11,777,000 [10-Q 2026-08-10]
What the company doesAI summary of filing
Bionano Genomics develops and sells optical genome mapping (OGM) systems, nucleic acid purification systems, genomic analysis software, and laboratory testing services for researchers and clinicians. The company's OGM systems—the Saphyr and Stratys instruments—detect structural variations in DNA and are marketed for applications in genetic disease research, cancer analysis, and cell and gene therapy. Bionano generates revenue from instrument sales, consumables (chips and reagents), software licenses, and laboratory testing services. The company is revenue-generating but has incurred recurring net losses since formation and faces substantial doubt about its ability to continue as a going concern without additional capital. [10-K 2026-03-23]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $14.86M | −$15.73M | −$10.39M | $3.73M | [10-Q 2026-08-10] |
| FY ended Dec 2025 | $28.51M | −$26.39M | −$16.34M | $2.99M | [10-K 2026-03-23] |
| FY ended Dec 2024 | $30.78M | −$112.02M | −$68.92M | $9.17M | [10-K 2026-03-23] |
- Quarterly cash burn
- −$5.19M
- Cash runway Estimate
- ~2.2 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-06 | 101,993,225 | [10-Q 2024-11-14] |
| 2025-03-24 | 3,007,000 | [10-K 2025-03-31] |
| 2025-05-07 | 3,364,000 | [10-Q 2025-05-14] |
| 2025-08-07 | 4,681,000 | [10-Q 2025-08-14] |
| 2025-11-05 | 10,176,000 | [10-Q 2025-11-13] |
| 2026-03-19 | 11,092,000 | [10-K 2026-03-23] |
| 2026-05-06 | 11,475,000 | [10-Q 2026-05-13] |
| 2026-08-06 | 11,777,000 | [10-Q 2026-08-10] |
- Shelf registration
- S-3 filed 2026-05-08; no effectiveness notice found in EDGAR [S-3 2026-05-08]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-04 | Luderer Albert | buy | 4,000 | $1.21 | [4 2026-09-09] |
| 2026-08-21 | Luderer Albert | buy | 4,000 | $1.22 | [4 2026-08-21] |
| 2026-06-03 | Dixon Jonathan V. | other | 24 | $1.30 | [4 2026-06-03] |
| 2026-06-03 | Oldakowski Mark | other | 27 | $1.30 | [4 2026-06-03] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-14 | 8-K | Regulation FD disclosure |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-10 | 10-Q | Quarterly report |
| 2026-08-10 | 8-K | Results of operations |
| 2026-06-24 | 8-K | Other events |
| 2026-06-05 | 8-K | Director or officer change |
| 2026-05-28 | 8-K | Other events |
| 2026-05-14 | 8-K | Shareholder vote results |
| 2026-05-13 | 10-Q | Quarterly report |
| 2026-05-13 | 8-K | Results of operations |
| 2026-05-08 | S-3 | Registration statement |
| 2026-05-06 | 8-K | Director or officer change; Other events |
Alerts for $BNGO
Email me when Bionano Genomics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.